10x Genomics slashed its FY24 revenue guidance from $640 million-$5660 million to $595 million-$605 million. 10x Genomics shares gained 6.3% to trade at $16.79 on Wednesday.

10x Genomics will host a conference call to discuss its third quarter 2024 results, business developments and outlook after market close on Tuesday, October 29, 2024 at 1:30 PM Pacific Time / 4:30 ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The ...

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all ...

So, it looks as if 10x is on track to report a step back in earnings growth. Looking ahead, 10x Genomics is set to provide full-year 2024 guidance during its upcoming earnings call scheduled for ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. PacBio. (2024, October 23). PacBio Onso™ short read sequencing instrument joins 10X Genomics ...

PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to ...